de la Rubia F, Clavo A, Lopez Prieto D, de Cueto M, Perez Ramos S, Sanchez Porto A, Lopez Sanchez A; International Conference on AIDS.
Int Conf AIDS. 1994 Aug 7-12; 10: 139 (abstract no. PB0568).
OBJECTIVE: This work was performed in order to define the antimicrobial susceptibility of Streptococcus pneumoniae in HIV+ patients and to analyze the possible differences with a control group HIV-. PATIENTS AND METHODS: From January 1993 to February 1994, 76 cases of pneumococcal infection (PI) were attended at the seven Hospitals included in GIDC, 17 of them affecting to HIV+ patients (CD4/mm3: 15.50 +/- 7.51). Every one of HIV+ patients was receiving antirretrovirals and cotrimoxazole prophylaxis. Antimicrobial susceptibility was performed by disc testing. CMI to penicillin (micrograms/ml) was performed by the E-test. RESULTS: There was no significative difference between HIV+ and HIV- groups when we considered the percentage of patients with resistance to antimicrobials chloramphenicol, tetracyclin, vancomycin, erythromycin, cefalotine, cefotaxime, ceftriaxone or teicoplanin. However the percentage of HIV+ patients with resistance to cotrimoxazol (HIV+ 75%, HIV- 61.5%, p < 0.04) or clyndamicin (HIV+ 57.1%, HIV- 13.1%, p < 0.002) was significantly increased when compared with HIV- patients. CMI to penicillin is shown in the table: TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS: 1) The antimicrobials erythromycin and cephalosporins, habitually employed in the treatment of the PI, are eficacious in the treatment of this entity in HIV+ patients. The resistance to cotrimoxazol may be related to the continuous use of the drug in the prophylaxis of Pneumocystis pneumonia. 2) In our area, there is no increment in the resistence to penicillin in HIV+ patients.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-Infective Agents
- Cefotaxime
- Chloramphenicol
- Communicable Diseases
- Erythromycin
- HIV
- HIV Infections
- HIV Seropositivity
- HIV-1
- Humans
- Pneumococcal Infections
- Streptococcus pneumoniae
- Trimethoprim-Sulfamethoxazole Combination
Other ID:
UI: 102209995
From Meeting Abstracts